As published in a press release by the Hereditary Neuropathy Foundation, a project funded by the National Institutes of Health (NIH), researchers at the University of
The FDA has recently granted the Fast Track designation to AGLE-102, a treatment for dystrophic epidermolysis bullosa. This designation will allow for the treatment to
When it comes to rare disease research and drug development, there is one crucial part of the equation: patient input. After all, how can companies
Near the end of September, Hansa Biopharma (“Hansa”) announced promising data from a Phase 2 clinical trial on imlifidase. This therapy is designed to treat
For years, clinical-stage biopharmaceutical company Fulcrum Therapeutics (“Fulcrum”) has worked to develop therapies for patients with rare genetic disorders and diseases. Somewhat recently, their focus
If you’re like me, you might be surprised that COVID-19 is not only still deeply ingrained in our world, but it seems to continue growing.
© Copyright Patient Worthy
